It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Franz Walt joined Quotient as the company’s Chief Executive Officer on April 2018. He serves as an supervisory board member of Epigenomics AG (FRA:ECX) since May 2019.
Epigenomics focuses on liquid biopsy tests for the detection of cancer with their proprietary DNA methylation biomarker technology. He brings over 30 years of experience in leadership roles at two of the largest, most influential healthcare companies, Siemens Healthineers and Roche, and serves as an expert advisor on the in-vitro diagnostics industry to manufacturing companies and private equity firms. His career has focused on business turnaround, above-market growth, profitability improvement, innovation, strategic alliances, quality, new product introduction, commercialization, media and investor relationship management. He served as President of Siemens Healthineers Laboratory Diagnostics from 2014 to 2017, where he had responsibility for global P&L and portfolio. In this role he led a turnaround, while bringing to market the first Siemens-engineered line of diagnostic instruments branded Atellica® and establishing complementary partnerships to build a growth portfolio. During his 23 years at Roche, he held positions of increasing responsibility in pharma and diagnostics, which includes CEO, Managing Director and President roles, in various geographic regions for Roche Diagnostics, also serving eight years as a member of the Roche Diagnostics Executive Committee (DiaEC). Walt served as a board member of the AdvaMed DX industry association, where he actively contributed to shape healthcare policy in diagnostic testing to improve patient health.
A Swiss national, he is fluent in German and English. He is a car enthusiast, and enjoys outdoor sports, photography, and spending time with his wife and two daughters. Walt holds an MBA from City University in Bellevue, Washington and completed executive programs at Columbia University, IMD, Switzerland, London Business School and INSEAD, France.
Peter Buhler joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2020. Mr Buhler has more than 20 years of experience in the strategic and financial leadership of life science and technology businesses in both the public and private sectors, more recently with Zaluvida AG, where he served as Group Chief Financial Officer.
In addition, Mr Buhler served as Group Chief Financial Officer of Greer Plc, a global leader in allergy immunotherapy headquartered in London.
While there, Mr Buhler led a complex merger project to combine a French and a US Group through the creation of a UK holding. Previously, he served as Head of Finance, Commercial Europe at Merck Serono SA and Finance Director EMEA at Logitech SA.
He is a Swiss Certified Accountant and an Executive MBA from the Swiss Business School in Zurich.
Jeremy Stackawitz joined Quotient (NASDAQ:QTNT) 10 years ago, overseeing the company through a period of sustained rapid growth. He led Quotient’s entry into the US market, where the company now serves over 1,000 customers and has successfully obtained over 60 FDA product approvals. He currently serves as President of Commercial and the Reagent Business.
He brings over 20 years of experience in healthcare, including diagnostics, pharmaceuticals and biotechnology. His past experiences include serving in various business development, general management and commercial roles for Johnson & Johnson, which included Commercial Director of Immunohematology for Ortho Clinical Diagnostics.
Previously he worked at Purdue Pharma running various Market Research and Commercial groups, and served as a Strategy Consultant to the healthcare industry with Monitor and McKinsey & Co consultancies.
Mr Stackawitz holds a BA in Chemistry from Dartmouth College and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania.
Edward Farrell joined Quotient (NASDAQ:QTNT) in February 2013 and serves as President of R&D and Manufacturing, overseeing the product development and manufacturing of MosaiQ™ in Switzerland and Scotland.
Mr Farrell has over 20 years of engineering, manufacturing and R&D experience in medical diagnostics in various roles including several senior positions.
While with Siemens Healthcare Diagnostics, Mr Farrell served as Managing Director and Vice President with responsibility for R&D and manufacturing, for a point-of-care diagnostic instruments and consumables facility, and subsequently, for a high-volume immunoassay reagent plant in the United Kingdom. Prior experiences at Siemens include, working in the United States as Director for a Distribution, Service and Repair site, and as a Senior Manufacturing Manager in a large diagnostic instrument manufacturing plant in Ireland. Previously Mr Farrell worked at Ingersoll Rand as a Production Manager, as Intel Manufacturing Engineer and Supervisor.
Mr Farrell received a BE (Mechanical) and a Masters in Engineering Science from University College Dublin.
Board of directors
Heino von Prondzynski, 65, served as chief executive officer of Roche Diagnostics and as a member of the executive committee of F. Hoffman-La Roche Ltd., a Swiss based healthcare company that develops diagnostics and therapeutic products, from early 2000 to 2006, retiring from Roche at the end of 2006. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including president of the vaccine business, at Chiron Corporation, a multinational biotechnology firm that developed biopharmaceuticals, vaccines and blood-testing products and was a member of the supervisory board at Koninklijke Philips Electronics NV, . Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer AG, a German based maker of healthcare products, specialty materials and agricultural products. Mr. von Prondzynski also serves on the boards of Hospira, Inc., Qiagen NV, and Epigenomics AG. Within the past five years, Mr. von Prondzynski also has served as a director of Nobel Biocare Holding AG, Switzerland (from 2010 to 2011). Mr. von Prondzynski studied maths, geography and history at Westfälische Wilhelms University, Münster, Germany.
Franz Walt joined Quotient as the company’s Chief Executive Officer in April 2018.
He brings 30 years of experience in leadership roles at two of the largest, most influential healthcare companies, Siemens Healthineers and Roche, and serves as an expert advisor on the in-vitro diagnostics industry to manufacturing companies and private equity firms. His career has focused on business turnaround, above-market growth, profitability improvement, innovation, strategic alliances, quality, new product introduction, commercialization, media and investor relationship management. He served as President of Siemens Healthineers Laboratory Diagnostics from 2014 to 2017, where he had responsibility for global P&L and portfolio. In this role he led a turnaround, while bringing to market the first Siemens-engineered line of diagnostic instruments branded Atellica® and establishing complementary partnerships to build a growth portfolio.
During his 23 years at Roche, he held positions of increasing responsibility in pharma and diagnostics – such as: CEO, Managing Director and President. The roles were based in various geographic regions for Roche Diagnostics, and he also served eight years as a member of the Roche Diagnostics Executive Committee (DiaEC). Mr. Walt served as a board member of the AdvaMed DX industry association, where he actively contributed to shape healthcare policy in diagnostic testing to improve patient health. A Swiss national, he is fluent in German and English. Mr. Walt also serves as a supervisory board member of Epigenomics AG (FRA:ECX) since May 2019. Epigenomics focuses on liquid biopsy tests for the detection of cancer with their proprietary DNA methylation biomarker technology. In his spare time, he is a car enthusiast, and enjoys outdoor sports, photography, and spending time with his wife and two daughters. Mr. Walt holds an MBA from City University in Bellevue, Washington and completed executive programs at Columbia University, IMD, Switzerland, London Business School and INSEAD, France.
Thomas Bologna is a Director, appointed in February 2012. Mr. Bologna is presently the Chairman and Chief Executive Officer of Response Genetics, Inc., a publicly-traded healthcare company focused on molecular diagnostics. From April 2006 until this appointment in December 2011, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a public corporation that provides DNA testing services. He was Chief Executive Officer, President, and a director of Quorex Pharmaceuticals, Inc. (2004 to 2005), a pre-clinical stage anti-infective company and Ostex International, Inc. (1997 to 2003), which developed, manufactured, and marketed products for the management of osteoporosis. From 1996 to 1997, Mr. Bologna was a principal at Healthcare Venture Associates, a consulting firm. He was Chief Executive Officer, President, and a director of Scriptgen Pharmaceuticals, Inc. (1994 to 1996), a biotechnology company that developed orally active drugs to regulate gene expression, and Chairman, President and Chief Executive Officer of Gen-Probe Incorporated (1987 to 1994), a company commercializing molecular diagnostics products. Mr. Bologna’s prior experience also includes senior- level positions with Becton Dickinson & Company and Warner-Lambert Company. Mr. Bologna currently serves as a director of Special Diversified Opportunities Inc., and has also served on the boards of several private companies, including Aperio Technologies until its sale to Danaher in 2012. Mr. Bologna received an M.B.A. and a B.S. from New York University.
Frederick Hallsworth is a Director, appointed in February 2011. Mr. Hallsworth spent 25 years with Arthur Andersen, becoming a partner in 1989. At Andersen, Mr. Hallsworth held a number of senior management positions, including Head of Corporate Finance, Head of Audit and Managing Partner of Andersen Cambridge, and Managing Partner and Head of Audit of Andersen Scotland. He joined Deloitte Scotland in 2002, where he served as Senior Client Service Partner, and Head of TMC Practice until 2005. He is also currently a director of memsstar (2006), CMA Scotland (2007), and Metaforic (2009). Former directorships include: Scottish Enterprise (2004-2010), Microvisk (2006-2012), Forth Dimension Displays (2007-2011), Elonics (2006-2010), Golden Charter (2009-2011), Infinite Data Storage plc (2005-2007), 3Way Networks (2005-2007), Innovata plc (2005-2007), and AT Communications plc (2008-2009). Mr. Hallsworth has been a Member of the Institute of Chartered Accountants of Scotland since 1978. Mr. Hallsworth received a Bachelor of Accountancy from Glasgow University 1974.
Brian McDonough is a Director, appointed in May 2012. Mr. McDonough is presently a Principal of Dx Consulting, a consultancy specializing in transfusion diagnostics. From 2003 through 2009, Mr. McDonough was Vice President, Worldwide Marketing, Donor Screening at Ortho Clinical Diagnostics, a Johnson and Johnson company. From 2000 through 2003, he was President of the North American Blood Products Group of the Medical Division of Pall Corporation, a company specializing in medical filtration products. Prior to holding these senior executive positions, Mr. McDonough had an extensive career at the American Red Cross spanning over 30 years. From 1968 through 1982, Mr. McDonough worked in American Red Cross BioMedical Services as Executive Head of the St. Louis Regional Blood Services Unit. In 1982, he became the Executive Director of the Irwin Memorial Blood Bank of San Francisco, where he also served on several public health committees addressing the spread of AIDS. In 1987, Mr. McDonough returned to the American Red Cross as Regional Vice President of BioMedical Services and in 1994 served under Elizabeth Dole as Chief Operating Officer, Blood Services of the American Red Cross BioMedical Services, with overall responsibility for national blood and plasma programs. Brian received a B.A. in liberal arts from Wichita State University and an M.H.A. from Central Michigan University
Sarah O’Connor, 54, served as the Senior Vice President, Strategic Development and Chief Legal Officer of Arch Chemicals, Inc., a global biocides company, where she was responsible for the company’s legal and strategic development functions, as well as enterprise risk management and government relations, from September, 2009 to October, 2011. Ms. O’Connor was Arch Chemicals, Inc.’s Vice President and General Counsel from February 1999 to September 2009. During this period Ms. O’Connor also had responsibility for Arch Chemicals’ Regulatory Affairs function. Prior to joining Arch Chemicals, Ms. O’Connor was an attorney in the legal departments of American Home Products Corporation and the Reader’s Digest Association. From September, 2012 to May, 2014, Ms. O’Connor was an adjunct professor at Mercy College and is a member of the school’s Development Committee. Ms. O’Connor received a B.S. in Business Administration from Mercy College, a J.D. from Fordham University School of Law and an MBA from Columbia University.
Zubeen Shroff is a Director, appointed in July 2013. Mr. Shroff is a Managing Director of Galen Partners, a leading healthcare growth equity firm founded in 1990. Mr. Shroff has 25 years of experience working with entrepreneurs and their Board of Directors in building high-growth healthcare companies. Mr. Shroff joined Galen in 1996, from The Wilkerson Group, where he was a Principal with a client base including pharmaceutical, diagnostics, device and biotech companies, plus a select number of venture capital firms. Prior to joining The Wilkerson Group, Mr. Shroff worked at Schering-Plough France, a manufacturer of healthcare products and medicines, where he helped launch their biotech product, alpha-Interferon, in several new indications. Currently, Mr. Shroff is Treasurer and on the Executive Committee of the Board for The Westchester Medical Center Public Benefit Corporation, as well as Chairman of its Foundation. Since 2004, he has served on the Advisory Committees to Boston University Medical School and The Center for Global Health & Development. In addition, Mr. Shroff is on the Advisory Board of the Joslin Diabetes Center. In addition to the above positions, over the past 10 years, Mr. Shroff has served on the Board of Directors of numerous privately held Galen portfolio companies in the industry. Mr. Shroff served on the public Board of Directors of Pet DRx Corporation until July 2010 and Encore Medical until June 2006. Mr. Shroff received a BA in Biological Sciences from Boston University and an MBA from the Wharton School, University of Pennsylvania.
Dr. John Wilkerson is a Director, appointed in February 2012. Dr. Wilkerson co-founded Galen Partners in 1990 and currently serves as a Senior Advisor to Galen. Dr. Wilkerson has focused on healthcare throughout his career, beginning as a Group Product Director for Ortho Diagnostics Inc., a Johnson & Johnson company. He was a Vice President covering medical device companies at Smith Barney before moving in 1980 to Channing, Weinberg & Co., Inc., a management consulting firm for pharmaceutical, diagnostic, medical device and biotechnology companies, which he purchased and renamed The Wilkerson Group (acquired by IBM in 1996). Dr. Wilkerson currently serves as a director Cardiva and TPS and was previously the Chairman of Atlantic Health Systems, a New Jersey hospital system. He is a trustee and former President of the Museum of American Folk Art and founder of the E. L. Rose Conservancy. Dr. Wilkerson received a Ph.D. from Cornell University.
|Audit Committee||Nominating and Governance Committee||Remuneration Committee||Strategy and Regulatory Committee|
|Heino von Prondzynski||Independent Director||Member||Chairperson||Member|
301 S State St
Newtown, PA 18940-1997
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Quotient Limited board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
- Product complaints
- Product inquiries
- New product suggestions
- Resumes and other forms of job inquiries
- Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
You may also communicate online with our Board of Directors as a group.